Diabetes mellitus is associated with bone loss. Patients with type 2 diabetes are frequently treated with oral antidiabetic drugs such as sulfonylureas, biguanides, and thiazolidinediones. Rosiglitazone treatment has been shown to increase adipogenesis in bone marrow and to induce bone loss. In this study we evaluated the effect of in vivo and in vitro treatment with metformin on bone marrow progenitor cells (BMPCs), as well as the involvement of AMPK pathway in its effects. The in vitro effect of coincubation with metformin and rosiglitazone on the adipogenic differentiation of BMPCs also was studied. In addition, we evaluated the effect of in vivo metformin treatment on bone regeneration in a model of parietal lesions in nondiabetic and streptozotocin-induced diabetic rats. We found that metformin administration both in vivo and in vitro caused an increase in alkaline phosphatase activity, type I collagen synthesis, osteocalcin expression, and extracellular calcium deposition of BMPCs. Moreover, metformin significantly activated AMPK in undiffer entiated BMPCs. In vivo, metformin administration enhanced the expression of osteoblast-specific transcription factor Runx2/Cbfal and activation of AMPK in a time-dependent manner. Metformin treatment also stimulated bone lesion regeneration in control and diabetic rats. In vitro, metformin partially inhibited the adipogenic actions of rosiglitazone on BMPCs. In conclusion, our results indicate that metformin causes an osteogenic effect both in vivo and in vitro, possibly mediated by Runx2/Cbfal and AMPK activation, suggesting a possible action of metformin in a shift toward the osteoblastic differentiation of BMPCs.
Introduction
L ong-standing diabetes mellitus has been associated with bone loss that can cause an increase in fracture risk/1 3> It has been suggested that these diabetes-associated bone alterations could be, at least in part, due to a pathologic accumulation of advanced glycation end products (AGEs) on bone extracellular matrix proteins.14'51 Different insulin sensitizers such as metfor min and thiazolidinediones (used as monotherapy or in combination) have proved to be efficient for the treatment of type 2 diabetes mellitus/61 It has been demonstrated previously that thiazolidinediones (e.g., rosiglitazone and netoglitazone) not only activate peroxisome proliferator-activated receptor gamma (PPAR7) but also suppress the expression and action of the osteoblast-specific transcription factor Cbfal.(7) Moreover, there is evidence that thiazolidinediones promote bone marrow stromal cell adipogenesis and inhibit osteogenesis. (8 10) Mice treated in vivo with thiazolidinediones decreased their bone mineral content, bone formation, and trabecular bone volume and increased adipogenesis/8,9,111 On the other hand, in patients with type 2 diabetes mellitus, metformin and sulfonylureas have been associated with a decreased risk of fracture/11 However, there is little information regarding the effect of these antidiabetic drugs on bone metabolism.
Our group has recently demonstrated that metformin causes a direct osteogenic action in a model of osteoblasts in culture/121 These actions include a dose-dependent increase in cell proliferation, type I collagen production, alkaline phosphatase (ALP) activity, and mineral deposition. These osteogenic actions of metformin appear to be mediated by an increase in the expression of nitric oxide synthases and in the activity of extracellular regulated kinases. Recently, Kanazawa and colleagues (13) have confirmed these results and suggested that metformin can induce the differentiation and mineralization of osteoblasts via activation of AMPK pathway and induction of endothelial nitric oxide synthase (eNOS) and bone morphoge netic protein-2 (BMP-2) expression.
Bone is a highly dynamic tissue/141 Cells of the bone marrow microenvironment appear to share common mesenchymal progenitor cells, which present the ability to differentiate into various cell types such as osteoblasts, adipocytes, and chondrocytes.115 171 In this context, bone marrow metabolic conditions are determinants of the biologic balance between osteoblast-mediated bone formation and marrow adipogenesis. (15) Diverse factors such as endogenous hormones and drug treatment can affect this delicate balance, modifying the osteoblast-adipocyte ratio in the bone marrow/151 In this context, a recent study has underlined the importance of PPAR7 in controlling the adipocyte-osteoblast relationship within the bone marrow cavity/181
In the present work, we have evaluated the in vivo and in vitro actions, as well as the possible mechanism of action, of metformin on bone marrow mesenchymal progenitor cells (BMPCs) and the effect of in vitro cotreatment with metformin and rosiglitazone on BMPCs. We also have investigated the effect of in vivo metformin administration on bone tissue regeneration in control nondiabetic and streptozotocin-induced diabetic rats. 
Materials and Methods

Animal treatment
Results
In vitro direct effect of metformin on BMPC osteoblastic differentiation In a first series of experiments, we evaluated the direct effect of metformin on BMPC differentiation to osteoblastic phenotype.
BMPCs from control rats were incubated in osteogenic medium containing increasing doses of metformin (0.5 to 10 pM). These doses are in the order of the plasma concentrations of metformin found in patients (10pM). (29) Osteogenic differentiation was evaluated by assessing the expression of extracellular type I collagen, ALP activity, and mineral deposits after 7, 15, and 21 days of culture. No differences were observed between control and metformin-treated cells after the first week of osteogenic differentiation (data not shown). After 15 days of differentiation, metformin significantly increased ALP activity, in a dose-dependent manner (Fig. 1A) . As explained in "Materials and Methods," production of type I collagen was first qualitatively assessed by Sirius red staining of cell monolayers (see Fig. IB ) and then quantified by extraction of the dye. As shown in Fig. 1C , metformin dose-dependently increases collagen production between 0.5 and lOpM. Additionally, collagen production of metformin-treated cells is significantly greater than in untreated cells at all metformin doses tested. This effect correlates with a greater mineralizing activity of metformin-treated cells, as evaluated by alizarin red staining of the cell monolayer (see Fig. ID ) and its quantification after extraction (see 
Metformin partially abolishes rosiglitazone-induced adipogenesis
To determine the effect of metformin on rosiglitazone-induced adipogenesis, BMPCs were committed to differentiate into adipocytes by treatment for 10 days with either rosiglitazone alone (0.5 pM) or rosiglitazone plus metformin (1 or 10 pM). Adipogenesis was evaluated through the enzymatic determina tion of intracellular lipid deposits in cell extracts and the staining of lipid droplets with oil red O in cell monolayers. BMPCs cultured in adipogénie medium without the addition of rosiglitazone presented intracellular lipid content below the detection limit of our enzymatic assay (data not shown). We found that metformin caused a significant dose-dependent decrease in the rosiglita zone-induced accumulation of intracellular triacylglycerides ( Fig. 2A) and of lipid droplets (see Fig. 2B ) when compared with cells treated with rosiglitazone alone. In parallel experi ments in which we substituted rosiglitazone with IBMX as inducer of adipogenesis, metformin also was found to induce a dose-dependent decrease in the accumulation of intracellular lipids (data not shown).
In vivo administration of metformin increases the in vitro osteoblastic differentiation of BMPCs
We next evaluated the effect of in vivo treatment with metformin on the osteogenic potential of BMPCs in vitro (i.e., the ex vivo effect of metformin on BMPCs). This drug was administered to rats in drinking water, as described in "Materials and Methods." After 15 days, BMPCs were obtained from control and metformin-treated rats and cultured until they reached confluence. After the first passage, the basal-specific activity Control 0 5 pM 1 pM 10 pM obtained from either control or metformin-treated rats in an osteogenic medium. After 15 days of differentiation, we found that BMPCs from metformin-treated rats expressed higher levels of ALP than BMPCs from control rats (Fig. 3A) and a significant increase in type I collagen production (see Fig. 38 ). Similarly, after 21 days of differentiation, we found a significant increase in osteocalcin expression (see Fig. 3C ) and in the formation of mineralization nodules (see Fig. 3D We stained the tissue sections with H&E to evaluate the following parameters: relative quantity of newly reossified bone (Fig. 4A-D) , the number of osteocytes immersed in reossified bone tissue (see Fig. 4£ ), and the number of osteoblasts on the surface of reossified bone (see Fig. 48 ). In addition, TRAP staining was performed to evaluate the proportion of reossified surface covered by osteoclasts (see Fig. 4F-J) . Histomorphometric analysis of the tissue sections is shown in Table 2 . Diabetic rats showed a decrease in the thickness, area, and osteoblast and A B Fig. 3 . Ex vivo effect of metformin on the osteoblastic potential of BMPCs. BMPCs isolated from control or metformin-treated (lOOmg/kg per day) rats were incubated in an osteogenic medium for 15 days, after which ALP activity (A) and type I collagen production (B) were measured, or BMPCs were cultured for 21 days, after which osteocalcin (C) and mineralization nodules (D) were evaluated. Values are expressed as mean ±SEM. *p < .05.
osteocyte density, of newly reossified bone when compared with nondiabetic rats. Metformin treatment induced a significant increase in the thickness and area of reossification in both control and diabetic rats without affecting osteoblast and osteocyte density. Interestingly, a significant 3.8-fold increase was observed in the TRAP activity of nondiabetic rats after 15 days of treatment with metformin.
Effect of ex vivo metformin treatment on osteoblastic and adipogenic transcription factors
We next evaluated possible changes in the expression of the two major transcription factors for osteoblastogenesis and adipo genesis, Cbfa1/Runx2 and PPARy (Fig. 5) . BMPCs from either control or metformin-treated rats were cultured in an osteogenic or adipogenic medium for the times indicated in the figures. Western immunoblot analysis showed that when compared with BMPCs from basal conditions (undifferentiated cells, time 0), BMPCs from metformin-treated rats expressed significantly more of the osteoblastic transcription factor Runx2 (see Fig. 5A ) but a similar amount of the adipogenic transcription factor PPARy (see Fig. 58 ). In addition, there was a time-dependent increase in Runx2 expression after 15 . However, when we probed with an antibody that recognizes the phosphorylated Thr172 in the a-subunit of AMPK, we found different results (Fig. 6A ). Metformin increased P-AMPK-associated fluorescence in both the cytoplasm and the nucleus. A semiquantitation of P-AMPK-associated fluorescence in metformin-treated BMPCs showed that P-AMPK expression was increased 1.5-fold versus untreated control cells in both the nucleus and the cytoplasm. The results obtained by immunofluorescence were further confirmed by Western immunoblotting (see Fig. 68 ). After 1 hour of incubation, lOOp.M metformin significantly increased by 1.6-fold the P-AMPK:AMPK ratio in BMPCs.
In other experiments we obtained BMPCs from both control and metformin-treated rats and submitted them to an osteogenic differentiation medium for 0, 15, or 21 days. After these periods of time, we evaluated both AMPK and P-AMPK in cell extracts by Western blotting. We found that ex vivo metformin induced a significant 2.8-fold increase in the P-AMPK:AMPK ratio after 21 days, with no observable difference for 0 or 15 days (see Fig. 6C ).
Discussion
Bone is a complex tissue containing several cell types that is continuously undergoing a process of self-renewal and repair termed bone remodeling.1''41 In aged people and in patients suffering from diabetes mellitus, bone remodeling is altered, and consequently, there is an increased skeletal fragility and fracture risk. '1-31 Sections of decalcified bone were stained with haematoxylin-eosin or tartrate resistance acid phosphatase (TRAP) (for osteoclasts) and quantitated In this study we have found that metformin also increases the ex vivo osteogenic potential of BMPCs; that is, the in vivo administration of metformin enhances BMPC osteoblastic ALP, type I collagen, osteocalcin, and mineral deposition in vitro (see Fig. 3 ) probably by increasing the expression of the Runx2/Cbfal transcription factor (see Fig. 5 ). Additionally, we created a parietal bone defect in nondiabetic and streptozotocin-induced diabetic rats, either untreated or treated with metformin. In untreated animals, we found that the diabetic state per se induces a significant decrease in bone healing, as evaluated by histomorphometric analysis (see Fig. 4 and Table 2 ). These results are in agreement with the previous report of Santana and collea gues/211 We also observed that metformin causes an increase in bone reossification at the lesion site in both diabetic and nondiabetic animals (see Fig. 4 and Table 2 ). In addition, metformin increases total osteoclastic activity in nondiabetic animals. These results with metformin probably reflect a concerted increase in bone formation and remodeling at the lesion site in a precisely regulated process that involves the localized coupling of osteoclasts with osteoblasts/22,341 Although we found that metformin induces an increase in bone reossification, it does not alter the glycemic profiles of either diabetic or nondiabetic rats (see Table 1 In addition, our present results indicate that metformin at clinically relevant doses (29) can partially block the proadipogenic effect of rosiglitazone on BMPCs (see Fig. 2) ; however, treatment with metformin does not affect expression of the transcription factor PPAFty versus control (see Fig. 58 In addition, the healing of the defect used in our study occurs in a relatively short period of time (15 days) , and the reossification process is intramembranous, meaning that its healing does not include soft callus formation, as in endochon dral bone repair, but involves direct bridging of the lesion by a hard callus of primary bone, which is then remodeled into mature bone by the combined action of osteoclasts and osteoblasts. (30) In our model of bone healing, metformin was found to simultaneously increase reossification and osteoclastic activity in the lesion site, suggesting a concerted increase in bone formation and remodeling.
Additionally, our results show in an in vitro model a reversion of rosiglitazone proadipogenic effects on BMPC differentiation by cotreatment with metformin. However, we cannot extra polate these results to humans. Further clinical investigations are needed to prove that this drug association has similar effects in human patients.
In conclusion, our results show that metformin increases the osteogenic induction of BMPCs both in vitro and in vivo and enhances the process of bone repair in diabetic and nondiabetic rats. The osteogenic actions of metformin on BMPCs are associated both with an increase in the expression of osteoblast-specific transcription factor Runx2/Cbfal and with an increase in the phosphorylation of AMPK. Moreover, metformin is able to partially inhibit the adipogenic action of rosiglitazone on BMPCs. Further investigations are needed to elucidate the in vivo significance of the inhibition by metformin of rosiglitazone-induced bone marrow adipogenesis.
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